Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of PBR-001 for myopic chorioretinal atrophy
jRCT2043200105Phase 1Suspended
- Sponsor
- Teijin Regenet
- Start
- Feb 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PBR-001 in degenerative myopia and Pathologic Myopia (PM), sponsored by Teijin Regenet. Primary endpoint: Percentage change in chorioretinal atrophic area. Started Feb 2021; status: suspended.
02
Drugs
PBR-001
03
Conditions
degenerative myopiaPathologic Myopia (PM)
Beyond the preview
Go deeper on jRCT2043200105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043200105.